Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference

Hassan R., Alexander R., Antman K., Boffetta P., Churg A., Coit D., ...Daha Fazla

ANNALS OF ONCOLOGY, cilt.17, sa.11, ss.1615-1619, 2006 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 17 Sayı: 11
  • Basım Tarihi: 2006
  • Doi Numarası: 10.1093/annonc/mdl060
  • Dergi Adı: ANNALS OF ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1615-1619
  • Anahtar Kelimeler: cancer, mesothelioma, peritoneal, MALIGNANT MESOTHELIOMA, PLEURAL MESOTHELIOMA, UNITED-STATES, ASBESTOS, EXPOSURE, INTRAPERITONEAL, CHEMOTHERAPY
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Peritoneal mesothelioma is a rare cancer of the peritoneum with about 250 new cases diagnosed each year in the United States. It is the second most common site for mesothelioma development and accounts for 10-20% of all mesotheliomas diagnosed in the United States. A meeting sponsored by the NIH Office of Rare Diseases was held in Bethesda, Maryland on September 13 and 14, 2004. The objective of this meeting was to review the epidemiology, biology and current surgical and medical management of peritoneal mesothelioma. In addition, the meeting also discussed clinical and pre-clinical evaluation of novel treatments for mesothelioma as well as ongoing laboratory research to better understand this disease. This report summarizes the proceedings of the meeting as well as directions for future clinical and basic research.